We conducted a multi-stage, genome-wide association study of bladder cancer with a primary scan of 591,637 SNPs in 3,532 affected individuals (cases) and 5,120 controls of European descent from five studies followed by a replication strategy, which included 8,382 cases and 48,275 controls from 16 studies. In a combined analysis, we identified three new regions associated with bladder cancer on chromosomes 22q13.1, 19q12 and 2q37.1: rs1014971, (P = 8 × 10 −12 ) maps to a non-genic region of chromosome 22q13.1, rs8102137 (P = 2 × 10 −11 ) on 19q12 maps to CCNE1 and rs11892031 (P = 1 × 10 −7 ) maps to the UGT1A cluster on 2q37.1. We confirmed four previously identified genome-wide associations on chromosomes 3q28, 4p16.3, 8q24.21 and 8q24.3, validated previous candidate associations for the GSTM1 deletion (P = 4 × 10 −11 ) and a tag SNP for NAT2 acetylation status (P = 4 × 10 −11 ), and found interactions with smoking in both regions. Our findings on common variants associated with bladder cancer risk should provide new insights into the mechanisms of carcinogenesis.
Bladder cancer is the fourth most common incident cancer in men 1 , and its frequent recurrence requires regular screening and inter ventions. Cigarette smoking and occupational exposure to aromatic amines have been strongly linked to bladder cancer risk 1 . A family history of bladder cancer is associated with an approximately twofold increase in risk of the disease, however, multiplecancer families are rare and no highpenetrance mutations have been identified to date in such families [2] [3] [4] . Large metaanalyses of candidate gene studies have provided support for associations between the NAT2 slow acetylation phenotype 5 (defined by NAT2 haplotypes) and a common gene dele tion of GSTM1 6 with bladder cancer risk 7, 8 . Further, geneenvironment interactions have been shown for both smoking and NAT2 acetylation, with an increased risk of bladder cancer in individuals who are slow acetylators being apparent only among cigarette smokers 7, 8 .
Previous genomewide association studies (GWAS) in bladder cancer have identified common variants in four genomic regions, on chromosomes 3q28 (TP63) 9 , 4p16.3 (TMEM129 and TACC3-FGFR3) 10 , 8q24. 21 (ref. 9 ) and 8q24.3 (PSCA) 11 , that are associated with risk. Notably, the variants on 8q24.21 map to a region centromeric to MYC that has been identified in GWAS of breast, colorectal and prostate cancers, as well as in GWAS of chronic lymphocytic leukemia [12] [13] [14] [15] [16] [17] [18] . Also, in followup analyses, an association with bladder cancer risk has been suggested for variants near the TERT-CLPTM1L locus on chromosome 5p15.33, which has also been associated through GWAS with risk for basal cell carcinoma, cutaneous melanoma, lung, brain and pancreatic cancers [19] [20] [21] [22] [23] . However, the previously reported association with bladder cancer at this locus did not achieve genome wide significance.
We conducted a multistage GWAS involving 3,532 cases and 5,120 controls of selfdescribed European descent in stage 1 and followed up the most significant signals in two stages of replication (stage 2a,b and stage 3) totaling 8,382 cases and 48,275 controls ( Fig. 1 11 . Five of these SNPs were further evaluated in a second scan of 1,274 cases and 1,832 controls in The Netherlands (stage 2b) 9 . Three of these five SNPs were included or tagged at a pairwise r 2 > 0.8 in the Dutch scan, and risk associations were confirmed for all three of these SNPs. In stage 3, these three SNPs plus a tagging SNP for NAT2 acetylation status were evaluated in 6,139 cases and 45,486 controls from 11 casecontrol studies and three prospective cohort studies from the United States and Europe ( Fig. 1 and Supplementary Table 1 ).
After quality control analysis of genotypes, we combined the data sets in stage 1, resulting in 591,637 SNPs available for analysis (based on the common SNPs called from both the Illumina Human1M and Human610Quad BeadChips) in 3,532 cases and 5,120 controls (Online Methods). We fit a logistic regression model for genotype trend effects (with 1 degree of freedom (d.f.)) adjusted for study center, age, sex, smoking status (with the categories current, former or never) and DNA source (blood or buccal). A quantilequantile plot showed little evidence for inflation of the test statistics as compared to the expected distribution (corrected λ 1,000 = 1.021), which minimized the likelihood of substantial hidden population substructure or Results of meta-analyses of allelic OR estimates for the markers reported to achieve genome-wide significance 25 . l e t t e r s differential genotype calling between cases and controls 24 (Online Methods and Supplementary Fig. 1 ). A Manhattan plot shows the results of the combined GWAS in stage 1 (Supplementary Fig. 2) . Data from the first stage confirmed the associations reported with tag SNPs in the four previously identified genomic regions on chromosomes 3q28 (rs710521) 9 11 and 4p16.3 (rs798766) 10 , as well as a suggested region in 5p15.33 (rs401681; a neighboring SNP, rs2736098, was also reported, but data for this SNP were not available in our study) 19 (Table 1 and Supplementary Fig. 3 ). Consistent with prior reports 9, 10 rs17642444  rs7836101  rs6586734  rs7827099  rs17517068  rs11203964  rs1110820  rs6994374  rs4921930  rs13265422  rs13259283  rs13250636  rs2035686  rs4921928  rs17595454  rs1995003  rs7817217  rs12544627  rs7817770  rs4921920  rs11785254  rs6997340  rs1390357  rs6586746  rs1466753  rs2410564  rs6998197  rs1495741  rs12545528  rs13276600  rs10103029  rs2410561  rs1495737  rs4646257  rs1390359  rs4646249  rs4646247   rs1208  rs7832071  rs1112005  rs1390358  rs7013253  rs13277723  rs1495750  rs7006687  rs1495754  rs6983849  rs2410554  rs13254048  rs2410552  rs10086768  rs10094010  rs6586740  rs11203956  rs1602782  rs1493037 rs10425059  rs4805470  rs12974501  rs13346555  rs759820  rs11669963  rs4805475  rs11672342  rs11667347  rs10406613  rs4804903  rs8102137  rs997669  rs1406  rs1862541  rs918587  rs10425066  rs728427  rs8110447  rs4805487  rs735319  rs7259542  rs11084240  rs8113773  rs17599667   rs34719  rs34722  rs4805495  rs34732  rs34707  rs4805496  rs34714  rs8111109 l e t t e r s on 8q24.21 and rs798766 on 4p16.3 were the SNPs most strongly associated with tumors of low grade and a low risk of progression (Supplementary Table 2) . A strong association with low grade and low risk disease was also suggested for rs401681 on 5p15.33 (Supplementary Table 2 ). In addition, we used a copy number vari ation TaqMan assay 7 to assess the presence of GSTM1 on 1p13.3 and to genotype stage 1 samples, and we confirmed an association with GSTM1 and increased bladder cancer risk ( Table 1) . In a combined analysis based on casecontrol counts by genotype and study, we estimated odds ratios (ORs) using logistic regression analyses adjusted for study center. Metaanalyses of estimated ORs adjusted for age, sex, smoking status and DNA source produced com parable point estimates (Supplementary Table 3) . Our combined analysis of stages 1, 2 and 3 identified three new genomic regions on chromosomes 22q13.1, 19q12 and 2q37.1 that were associated with bladder cancer risk below the threshold for genomewide significance (P < 5 × 10 −7 ) 25 (Table 2, Supplementary Fig. 4 for study and stagespecific estimates and Fig. 2) . We also confirmed a signal below genomewide significance for rs1495741, which tags the NAT2 acetylator status 26 Table 2 ). This locus is located in a nongenic region approximately 25 kb centro meric of APOBEC3A (encoding the catalytic polypeptidelike 3A) and 64 kb telomeric of CBX6 (encoding the chromobox homolog 6). APOBEC3A encodes an apolipoprotein B mRNAediting enzyme and belongs to the cytidine deaminase gene family, which can play a role in the initiation of tumorigenesis by deamination of cyto sine to uracil 27 . CBX6 is a component of the chromatinassociated polycomb complex involved in transcriptional repression.
In the combined analysis, we observed an association with rs8102137 on chromosome 19q12 (P trend = 1.7 × 10 −11 , OR per C allele = 1.13, 95% CI 1.09-1.17), which maps to CCNE1, the cyclin E1 gene. CCNE1 is a key member of the cyclindependent kinase (Cdk)retinoblastoma protein (pRB) pathway which determines the rate of cell cycle transition from the G1 to the S phase and is commonly altered in bladder cancer and other tumors 28 . Cyclin E1 expression in bladder cancer has been associated with highgrade or muscleinvasive tumors and poor clinical outcome 29 . Consistently, rs8102137 was most strongly associated with risk of high grade, high risk tumors (Supplementary Table 2) .
A third locus is marked by rs11892031 (P = 1.0 × 10 −7 , OR per C allele = 0.84, 95% CI 0.79-0.89) on chromosome 2q37.1 and resides in an intronic region of the locus on UGT1A, the uridine 5′ diphospho glucuronosyltransferase 1A gene, which encodes the UGT1A family of proteins. Glucuronidation by UGTs facilitates solubility and removal of substrates such as endobiotics and xenobiotics (including carcinogens in tobacco smoke) through bile or urine 30 . Genetic vari ation in UGT1A has been associated with predisposition to severe gastrointestinal toxicity to the anticancer drug irinotecan 31 . The UGT1A locus is represented by at least nine highly homologous tran scripts, collectively known as UGTs, generated by alternative splicing. Tissuespecific loss or decreased expression of UGTs has been associated with several gastrointestinal cancers and bladder cancer [32] [33] [34] as well as experimentally induced bladder cancer in animal models 35 .
Previously, a promising signal in the CLPTM1L-TERT locus on chromosome 5p15.33 was reported in a region in which common variants have been associated with multiple cancers in recent GWAS [19] [20] [21] [22] [23] . In addition, rare mutations in TERT have been linked to dyskeratosis congenita (a bone marrow failure syndrome), idiopathic pulmonary fibrosis, acute myelogenous leukemia and chronic lympho cytic leukemia [36] [37] [38] [39] . In the first stage of this GWAS, we observed a moderately significant effect for rs401681 (P = 2.9 × 10 −3 ), which was at genomewide significance when combined with the data from a previous report 19 (P = 5.0 × 10 −7 , OR per C allele 1.11, 95% CI 1.07-1.16) ( Table 1 and Supplementary Fig. 3) .
The risk associated with GSTM1 and NAT2 varied in strength across categories of cigarette smoking, whereas genotype risk asso ciations by smoking categories were of similar magnitude for the eight susceptibility loci identified by our GWAS (Supplementary Table 4 ). In a combined analysis, the risk association with GSTM1 deletion was strongest in never smokers (OR = 1.71, 95% CI 1.38-2.12) and grew progressively weaker in former (OR = 1.62, 95% CI 1.39-1.89) and current smokers (OR = 1.19, 95% CI 1.00-1.40, P for interaction = 0.008 for current versus never smokers; Table 3 ). The stronger association of the GSTM1 deletion among nonsmokers is a new observation that was not evident in previous caseonly meta analyses 7 . rs1495741, located on the 3′ end of NAT2, is a marker of the NAT2 phenotype associated with bladder cancer risk 26 . The l e t t e r s rs1495741 AA genotype, which marks the slow acetylation pheno type as compared to the combined GG and AG genotypes which correspond to the intermediate and rapid acetylation phenotypes, respectively, showed a highly significant (P = 5.5 × 10 −7 ) associa tion with increased bladder cancer risk that was limited to cigarette smokers (OR = 1.24, 95% CI 1.16-1.32, P = 1.3 × 10 −10 , P for inter action = 2.8 × 10 −4 ) ( Table 3 and Supplementary Fig. 5 ). This inter action is consistent with the role of NAT2 in the detoxification of bladder carcinogens such as aromatic amines from tobacco smoke. Our threestage study had adequate power to detect variants of moder ate effect sizes over a range of common allele frequencies. For the newly discovered SNP markers, the power to detect the observed associations at a level of genomewide significance was 54%, 30%, 30% and 6% for rs104971, rs1495741, rs8102137 and rs11892031, respectively. In light of the limited power to discover SNPs with modest effect sizes, additional loci with similar effect sizes will likely be identified in larger scale GWAS. Based on a recent estimator 40 that incorporates new and previously reported loci together, we estimate that approximately two dozen addi tional bladder cancer susceptibility SNP markers of similar magnitude and frequencies remain to be discovered. Future studies should be powered with adequate sample size to detect additional variants.
With the exception of the GSTM1 deletion, the relative risk estimates for new loci are based on associations using tag SNPs, which most likely underestimate the association to biologically important alleles. Accordingly, further studies are needed to define the functional variants and the clinical utility of risk models that combine genetic markers with other risk factors for bladder cancer (that is, smoking, occupational and environmental exposures and family history). Our combined analy sis of 11,914 individuals with bladder cancer and 53,395 controls has uncovered three new genomic regions associated with bladder cancer risk. Finemapping studies of these three regions are needed to iden tify candidate variants for functional studies that could shed light into biological mechanisms for the associations reported through GWAS. This knowledge could establish the foundation for developing improved preventive, diagnostic and/or therapeutic approaches.
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